AbbVie’s Humira Revenue Up 15% (Despite Patent Cliff Fears)
April 27, 2017 at 16:54 PM EDT
Will discuss why AbbVie’s earnings report was better than anticipated, and what investors can expect from this stock moving forward.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.